D. Cardiomyocyte injury mediated by topoisomerase IIβ-related DNA damage and oxidative stress
Why this is correct
Anthracyclines such as doxorubicin can cause dose-related cardiomyopathy. Myocardial injury involves topoisomerase IIβ-associated DNA damage, mitochondrial dysfunction and oxidative stress, culminating in cardiomyocyte dysfunction or death. Chronic injury can lead to dilated cardiomyopathy and heart failure with reduced ejection fraction. Contemporary cardio-oncology monitoring emphasizes baseline risk, exposure and serial ventricular function assessment.
Why each option is correct or incorrect
Beta-1 receptor blockade is not the pathogenesis of anthracycline myocardial toxicity.
Prostaglandin-mediated ductal dilation pertains to fetal/neonatal ductal physiology.
Right-sided valvular fibrous plaques are classically linked to carcinoid disease, not anthracyclines.
Correct: anthracycline-related myocardial toxicity involves topoisomerase IIβ, DNA injury and oxidative stress.
High-yield notes
- Doxorubicin is associated with dose-related cardiomyopathy.
- Mitochondrial injury and oxidative stress contribute to toxicity.
- Dilated LV and reduced EF may appear after anticancer treatment.
Anthracycline exposure + later dilated cardiomyopathy is a classic exam association.
Trastuzumab-related dysfunction has a different mechanism and may have a different reversibility profile; do not treat the two toxicities as identical.